Fig. 1 · Structure

Documents & Downloads

Motesanib (AMG706)

Cat. No. A11496 CAS 453562-69-1

VEGFR Inhibitor

Motesanib (AMG706) is a multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors (PDGFRs), and Kit receptors with IC, values of 2 nM (VEGFR1), 3 nM (VEGFR2), 6 nM (VEGFR3), 84 nM (PDGFR), and 8 nM (Kit).

In Stock

Publications for Motesanib

1 publication citing this product

  1. Ayaka Kojima, .et al. , Xenobiotica, 2022, Jul;52(7):669-675 PMID: 36251932

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Motesanib inhibited VEGFR2 kinase activity in a cell-free kinase assay, with activity decreasing across serial drug dilutions. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
VEGFR1 IC50 2 nM
VEGFR2 IC50 3 nM
VEGFR3 IC50 6 nM

Motesanib (AMG706) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Motesanib (AMG706) from 2 published references.

Motesanib (AMG706) In Vitro Studies

Motesanib reduced VEGF-stimulated HUVEC proliferation over four days at 5–25 nM. At 25 nM without added VEGF, no significant antiproliferative effect was reported. [1]

In a 72-hour proliferation assay, motesanib had an IC50 of 10 nM in VEGF-stimulated HUVECs and >5,000 nM in each of five NSCLC cell lines. These findings indicate a strong dependence on cellular context. [2]

VEGFR2 kinase activity

Biochemical assay · VEGFR2 kinase activity measured with the HTScan VEGF Receptor 2 Kinase Assay Kit [1]

Motesanib reduced VEGFR2 kinase activity across serial dilutions. The study supports VEGFR2 inhibition without establishing a numerical IC50 in this record.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
VEGFR2 kinase activityQualitative concentration response Concentration-dependent reduction in kinase activity[1]

Literature-Reported Treatment Conditions

Treatment concentration
Serial dilutions of motesanib (Figure 1B)
Method
In vitro VEGFR2 kinase assay according to kit instructions
Reported limits
Main text does not specify assay incubation time, ATP concentration, replicate number or vehicle for this kinase assay; these are not borrowed from cellular experiments.
Methods and source locations

Compound reported in the paper: Motesanib; Compound label in the paper: Motesanib as reported; salt form unspecified

Findings apply to the reported motesanib preparation and experimental conditions; no salt conversion or product-lot validation is implied.

Materials and Methods: VEGFR kinase assay; Results: Motesanib has specific activity on HUVECs in vitro; Figure 1B and caption

VEGFR2 kinase activity: HTScan VEGF Receptor 2 Kinase Assay Kit; activity plotted as percent kinase activity. No IC50 estimated from the curve. — Figure 1B; Materials and Methods: VEGFR kinase assay

VEGF-dependent HUVEC proliferation

Cell-based study · Human umbilical vein endothelial cells in EBM-2 basal medium with 2% FBS and no added growth supplements [1]

Motesanib inhibited VEGF-stimulated proliferation in a concentration-dependent manner. At 25 nM without added VEGF, no significant antiproliferative effect was reported.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
VEGF-stimulated HUVEC proliferationCrystal violet staining Concentration-dependent inhibition; mean ± SEM, 6 wells per condition[1]
HUVEC proliferation without added VEGFQualitative negative control No significant antiproliferative effect reported at 25 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Motesanib 5, 10 and 25 nM with VEGF; 25 nM in the no-added-VEGF control
Exposure duration
4 days
Method
VEGF stimulation: 25 ng/mL every 24 hours; crystal violet proliferation assay
Vehicle
0.25% DMSO in all wells
Co-treatment
VEGF stimulation, not an anticancer-drug combination
Reported limits
Six wells per condition are reported; number of independent biological repeats is not specified in the retrieved assay description.
Methods and source locations

Compound reported in the paper: Motesanib; Compound label in the paper: Motesanib as reported; salt form unspecified

Findings apply to the reported motesanib preparation and experimental conditions; no salt conversion or product-lot validation is implied.

Materials and Methods: HUVEC proliferation assays, Crystal violet assay; Results: Motesanib has specific activity on HUVECs in vitro; Figure 1A and caption

VEGF-stimulated HUVEC proliferation: Crystal violet staining intensity after 4 days; VEGF 25 ng/mL every 24 hours. No numerical IC50 reported for this assay. — Figure 1A and caption; Materials and Methods: Crystal violet assay

HUVEC proliferation without added VEGF: Basal medium comparison with vehicle and 25 nM motesanib, without added VEGF. — Figure 1A; Results: Motesanib has specific activity on HUVECs in vitro

Endothelial versus NSCLC proliferation response

Cell-based study · HUVECs stimulated with VEGF; A549, Calu-6, NCI-H358, NCI-H1650 and NCI-H1299 NSCLC cells [2]

Motesanib had a reported proliferation IC50 of 10 nM in VEGF-stimulated HUVECs and >5000 nM in each of five NSCLC cell lines. Docetaxel inhibited all tested cell lines, providing a pharmacological comparator.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
VEGF-stimulated HUVEC proliferationIC50 10 nM[2]
Proliferation of A549, Calu-6, NCI-H358, NCI-H1650 and NCI-H1299IC50 >5000 nM for each cell line[2]
Docetaxel comparator proliferation responseIC50 HUVECs: <1 nM; A549, Calu-6, NCI-H358 and NCI-H1650: <10 nM; NCI-H1299: <50 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Motesanib 0.0025–5000 nM; separate comparator docetaxel 0.001–5000 nM (10-point serial dilutions)
Exposure duration
72 hours after overnight plating
Method
NSCLC cells in DMEM high glucose with 10% FBS and 2 mM L-glutamine; HUVEC motesanib assay in DMEM high glucose with 2 mM L-glutamine and 50 ng/mL recombinant human VEGF
Vehicle
Motesanib in medium containing 1% DMSO; docetaxel in PBS
Co-treatment
None in the adopted single-agent panel; docetaxel is a separate comparator
Reported limits
Duplicate treatments are reported; independent biological repeat count is not specified. The figure curve/control labels include PBS and 0 nM motesanib; a separate DMSO-only curve is not identified.
Methods and source locations

Compound reported in the paper: Motesanib; Compound label in the paper: Motesanib as reported; salt form unspecified

Findings apply to the reported motesanib preparation and experimental conditions; no salt conversion or product-lot validation is implied.

Methods: In vitro cell proliferation assays; Results: Expression of VEGFR2 and effect of motesanib on NSCLC tumor cell proliferation; Figure 1B–C and caption

VEGF-stimulated HUVEC proliferation: ATPlite 1-step luminescence viability assay after 72 hours; treatments in duplicate. — Figure 1B–C; Methods: In vitro cell proliferation assays

Proliferation of A549, Calu-6, NCI-H358, NCI-H1650 and NCI-H1299: ATPlite 1-step luminescence viability assay after 72 hours; treatments in duplicate. — Figure 1B–C; Methods: In vitro cell proliferation assays

Docetaxel comparator proliferation response: Same cell panel and 72-hour viability assay; docetaxel tested separately from motesanib. — Figure 1B; Methods: In vitro cell proliferation assays

Motesanib (AMG706) In Vivo Studies

In established Calu-6 xenografts, oral motesanib at 75 mg/kg twice daily for 17 days produced 66% tumor growth inhibition versus vehicle. The 37.5 mg/kg twice-daily and 75 mg/kg once-daily schedules did not significantly inhibit growth. Body weight remained similar to vehicle during this experiment. [2]

Calu-6 xenograft monotherapy dose and schedule comparison

Animal study · Established subcutaneous Calu-6 human NSCLC xenografts in female CD1 nu/nu mice [2]

Of the tested motesanib schedules, only 75 mg/kg twice daily significantly inhibited Calu-6 tumor growth, with 66% inhibition versus vehicle. Lower schedules did not produce significant inhibition. Body weights remained similar to vehicle during this experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Calu-6 xenograft tumor growth versus vehicleTumor growth inhibition 66% at 75 mg/kg BID; P < 0.05 versus vehicle[2]
Body weight during Calu-6 monotherapyQualitative tolerability index Body weights remained stable and similar to vehicle[2]

Conditions shared by the study groups

Route
Oral
Treatment course
17 days
Vehicle
Water, pH 2.5
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
VehicleVehicle armReference control for tumor growth and body weight[2]
Motesanib 37.5 mg/kg BIDWater vehicle controlNo significant tumor growth inhibition versus vehicle reported[2]
Motesanib 75 mg/kg QDWater vehicle controlNo significant tumor growth inhibition versus vehicle reported[2]
Motesanib 75 mg/kg BIDWater vehicle control66% tumor growth inhibition versus vehicle; P < 0.05[2]
Vehicle
Model: Established Calu-6 subcutaneous xenografts in female CD1 nu/nu mice
Frequency: Matched vehicle schedule
Reported limits: 9–10 mice per group reported across xenograft protocols; exact n for this arm not specified.
Motesanib 37.5 mg/kg BID
Model: Established Calu-6 subcutaneous xenografts in female CD1 nu/nu mice
Frequency: Twice daily
Reported limits: 9–10 mice per group reported across xenograft protocols; exact n for this arm not specified.
Motesanib 75 mg/kg QD
Model: Established Calu-6 subcutaneous xenografts in female CD1 nu/nu mice
Frequency: Once daily
Reported limits: 9–10 mice per group reported across xenograft protocols; exact n for this arm not specified.
Motesanib 75 mg/kg BID
Model: Established Calu-6 subcutaneous xenografts in female CD1 nu/nu mice
Frequency: Twice daily
Reported limits: 9–10 mice per group reported across xenograft protocols; exact n for this arm not specified.
Methods and source locations

Compound reported in the paper: Motesanib; Compound label in the paper: Motesanib as reported; salt form unspecified

Findings apply to the reported motesanib preparation and experimental conditions; no salt conversion or product-lot validation is implied.

Results: Effect of single-agent motesanib on human NSCLC tumor growth; Figure 2B and caption; Table 1 Calu-6 row; Methods: Tumor xenograft models and Statistical analysis

Calu-6 xenograft tumor growth versus vehicle: Caliper measurements twice weekly; Calu-6 volume calculated as length × width × height. Repeated-measures ANOVA with post hoc testing as described; Table 1 specifies data from a single experiment. — Figure 2B; Table 1 Calu-6 row; Results: Effect of single-agent motesanib; Methods: Tumor xenograft models and Statistical analysis

Body weight during Calu-6 monotherapy: Body weights recorded twice weekly; this limited index does not establish general safety. — Figure 2B lower panel; Results: Effect of single-agent motesanib; Methods: Tumor xenograft models

Vehicle · Figure 2B and caption; Table 1 Calu-6 row; Methods: Tumor xenograft models

Motesanib 37.5 mg/kg BID · Figure 2B and caption; Table 1 Calu-6 row; Methods: Tumor xenograft models

Motesanib 75 mg/kg QD · Figure 2B and caption; Table 1 Calu-6 row; Methods: Tumor xenograft models

Motesanib 75 mg/kg BID · Figure 2B and caption; Table 1 Calu-6 row; Methods: Tumor xenograft models

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 453562-69-1
Applications VEGFR Inhibitor
Formula C22H23N5O
Molecular Weight 373.45
Synonyms AMG 706
SMILES
CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 68 mg/mL (182.09 mM)
Water Insoluble
Ethanol 7 mg/mL (18.74 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Motesanib (AMG706) Research References

  1. [1] Kruser TJ, Wheeler DL, Armstrong EA, et al. Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20507929 DOI: 10.1158/1078-0432.ccr-09-3385 Source material
  2. [2] Coxon A, Ziegler B, Kaufman S, et al. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Molecular cancer (2012). PMID: 22992329 DOI: 10.1186/1476-4598-11-70 Source material

Publications

1 publication citing this product

  1. Ayaka Kojima, .et al. , Xenobiotica, 2022, Jul;52(7):669-675 PMID: 36251932

Added to your cart

View Cart Checkout
Loading...